A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Celecoxib (Primary) ; Antineoplastics
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms BOXIT
- 18 Sep 2019 Status changed from active, no longer recruiting to completed.
- 05 Sep 2012 Accrual to date is 99% according to United Kingdom Clinical Research Network.
- 05 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.